Summary of the Conference Call Transcript Company Overview - The company discussed is **Yuan Dong Bio** (苑东生物), operating in the pharmaceutical industry, particularly focusing on controlled narcotics and innovative drug development. Key Financial Highlights - **2025 Financial Performance**: - Total revenue: **¥1.331 billion** (down **1.36%**) - Net profit attributable to shareholders: **¥283 million** (up **18.89%**) - Non-recurring net profit: **¥206 million** (up **18.01%**) - Q4 revenue: **¥312 million** (up **0.8%**) - Q4 net profit: **¥63 million** (up **197.2%**) - Q4 non-recurring net profit: **¥33 million** (up **376.9%**) [1][2] - **Adjusted Profit Forecast**: - If stock incentive expenses are excluded, the net profit for 2025 is expected to exceed **¥300 million** [2]. Revenue Drivers and Challenges - Revenue decline attributed to the **10th batch of national procurement**, with three products (Naloxone, Shuqing, and Nortriptyline) expected to drop by over **¥150 million**. - Despite this, products like Nabuphine, Butorphanol, and others are maintaining good growth, leading to overall revenue stability [2]. Profitability and R&D Focus - The company is actively integrating its R&D system and controlling costs for generic drugs and some innovative drugs. - Despite additional R&D expenses from the consolidation of Shanghai Chaoyang, the overall R&D expense ratio is expected to improve, a trend anticipated to continue into 2026 [2]. Future Growth Prospects - **2026 Revenue Expectations**: - Revenue from controlled narcotics is projected to increase from **¥60 million** in 2025 to over **¥200 million**, driven by products like Nabuphine, Butorphanol, Ephedrine, and Oxazepam. - Approval of Acetaminophen-Oxycodone and Morphine-Naloxone is imminent, with participation in annual medical insurance negotiations expected [3]. - **Profit Growth**: - The company is expected to achieve a **20% profit growth** in 2026 [3]. R&D Developments - **Shanghai Chaoyang Platform**: - **HP-001 (IKZF1/3 molecular glue)**: Best-in-class single-agent data, currently in Phase IIa clinical trials with potential for conditional marketing approval. - **HP-002 (BTK PROTAC)**: IND submission expected soon, with preclinical data outperforming competitors. - **HP-003 (VAV1 molecular glue)**: Anticipated to be a new star in autoimmune potential, with Phase II POC data expected in mid-2026 and IND submission planned for H2 2026 [3][4]. - **DAC Platform**: - The company has established a complete targeted protein degradation platform, with competitive advantages in both TPD and DAC fields. The first DAC molecule, HP-004, shows significantly better data than combination therapies and is entering the Pre-IND stage [4].

Core Insights - The company reported Q3 2025 revenue of 365 million yuan (-1.55%) and a net profit attributable to shareholders of 83.59 million yuan (+18.52%, including stock incentive expenses), with a non-GAAP net profit of 69.19 million yuan (+27.85%, including stock incentive expenses), indicating a significant profit surprise due to new product launches and controlled investment in generic drug R&D [1] Group 1: Business Performance - The main business has reached a turning point, with expectations for a return to high growth. The impact of the tenth batch of national procurement has pressured H1 2025 performance, but the second half is expected to benefit from a low base, gradually alleviating procurement pressures [2] - Core products such as Butorphanol, Nalbuphine, and Oxazepam have entered a rapid growth phase, with Q3 2025 operational trends expected to continue and accelerate [2] Group 2: Internationalization and Innovation - The company has achieved breakthroughs in internationalization, with the Naloxone nasal spray production line passing FDA pre-approval inspections with zero defects and awaiting the final inspection report. Exclusive commercialization agreements have been signed with agents in the U.S. and Canada [2] - Strategic control of Chaoyang Pharmaceutical has strengthened the innovation engine, with the company increasing its stake to 51.48% and integrating its core pipeline into the company's innovation system [3] - The progress of Chaoyang's pipeline is promising, with the core product HP-001 showing good safety in Phase I clinical trials and demonstrating "Best-in-Class" potential [3] - The company has also made breakthroughs in independent R&D, with multiple projects entering clinical trials, including the ADC drug YLSHO03 and the third-generation calcium channel modulator EP-02260 [3] Group 3: Investment Outlook - The company is rapidly launching new products while actively adjusting R&D investments in generics. Despite the significant impact of the tenth batch of national procurement, the company is expected to unlock stock incentive profit assessment indicators for the year [4] - Profit forecasts have been adjusted, with expected net profits for 2025-2027 at 277 million, 339 million, and 423 million yuan, representing year-on-year growth of 16.2%, 22.5%, and 24.7% respectively [4] - The rapid progress of Shanghai Chaoyang's innovative drugs has led to an adjustment in valuation models, with a target market value of 14.6 billion yuan and a target price of 82.5 yuan, maintaining a "strong buy" rating [4]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's Q2 2025 performance shows significant improvement, with a quarter-on-quarter revenue increase of 14.12% and a net profit increase of 25.40% [4] - The company is expected to continue achieving its stock incentive goals, driven by new product launches and accelerated overseas revenue growth [4] - The projected net profits for 2025-2027 are 271 million, 319 million, and 379 million yuan respectively, with corresponding EPS of 1.53, 1.80, and 2.15 yuan [4] Financial Summary - For H1 2025, the company reported revenue of 654 million yuan (down 2.25% year-on-year) and a net profit of 137 million yuan (down 6.77% year-on-year) [4] - Q2 2025 revenue was 349 million yuan (down 1.61% year-on-year, up 14.12% quarter-on-quarter) and net profit was 76 million yuan (up 6.29% year-on-year, up 25.40% quarter-on-quarter) [4] - The company’s revenue is projected to grow from 1,532 million yuan in 2025 to 2,109 million yuan in 2027, with a year-on-year growth rate of 13.5% and 18.5% respectively [8] Business Development - The company has recently received approvals for new products, including sodium nalbuphine injection and butorphanol tartrate injection, contributing to revenue growth [5] - The company is actively expanding its international market presence, with regular shipments of nicardipine hydrochloride injection and plans for a naloxone nasal spray submission in September 2024 [5] - The company has increased its stake in Chao Yang to 30.68%, enhancing its innovation platform value [6]